About: Immune Cell Profiling of COVID-19 Patients in the Recovery Stage by Single-Cell Sequencing

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Immune Cell Profiling of COVID-19 Patients in the Recovery Stage by Single-Cell Sequencing Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Immune Cell Profiling of COVID-19 Patients in the Recovery Stage by Single-Cell Sequencing
Creator	Chen, Wei Cui, ; Dong, Jiantao Hao Tang, ; Le, Wenqing Li, Jianmin Liu, Xiuxing Miao, Yushan Su, Wenru Wang, Depeng Wang, Hongyang Wen, Wen Xiao, Chuanle Xie, ; Ye, Jinguo Zhang, ; Zheng, Yingfeng
topic	covid:8c27de904a8b18419ec9e5b882a90d0b72838f4a#this
source	MedRxiv
abstract	COVID-19 caused by SARS-CoV-2 has recently affected over 200,000 people and killed more than 8000. Immune system dysregulation such as lymphopenia and inflammatory cytokine storm has been observed in COVID-19 patients, but it remains unclear for the change of key immune cell subsets and their states during COVID-19. Here, we applied single-cell technology to comprehensively characterize transcriptional changes of peripheral blood mononuclear cells in ten patients recovered from COVID-19. Compared with healthy control, COVID-19 induced a unique signature of immune cells in humans, especially in the early recovery stage (ERS). In ERS patients, T cells were decreased remarkably, while monocytes were increased. A detailed analysis of monocytes showed that there was an increased ratio of classical CD14++ monocytes with highly inflammatory genes expression, as well as a greater abundance of CD14++IL1B+ monocytes. For nature killer (NK) cells and T cells, CD4+ T cells were significantly decreased and expressed high level of inflammatory markers, while NK cells were increased. In addition, T cells were highly expanded clone, especially in CD4+ T memory cells and CD8+ T cells. Among B cells, plasma cells were increased remarkably, and naïve B cells were reduced. Our study also identified several novel B cell receptor (BCR) changes (such as IGHV1-8 and IGHV3-7), and confirmed isotypes (IGKV3-11 and IGHV3-21) previously used for virus vaccine development. The strongest pairing frequencies, IGHV3-23+IGHJ4, indicated a monoclonal state associated with SARS-CoV-2 specificity. Furthermore, integrated analysis predicated that IL-1B and M-CSF may be novel candidate target gene for inflammatory storm, and TNFSF13, IL-18 and IL-4 may be benefit for the recovery of COVID-19 patients. Our study provides the first evidence of inflammatory immune signature in early recovery stage, suggesting that the COVID-19 patients are still vulnerable after hospital discharge. Our identification of novel BCR signaling may lead to the development of vaccine and antibodies for the treatment of COVID-19.
has issue date	2020-03-27(xsd:dateTime)
bibo:doi	10.1101/2020.03.23.20039362
has license	medrxiv
sha1sum (hex)	8c27de904a8b18419ec9e5b882a90d0b72838f4a
schema:url	https://doi.org/10.1101/2020.03.23.20039362
resource representing a document's title	Immune Cell Profiling of COVID-19 Patients in the Recovery Stage by Single-Cell Sequencing
resource representing a document's body	covid:8c27de904a8b18419ec9e5b882a90d0b72838f4a#body_text
is http://vocab.deri.ie/void#inDataset of	https://covidontheweb.inria.fr:4443/about/id/http/ns.inria.fr/covid19/8c27de904a8b18419ec9e5b882a90d0b72838f4a
is schema:about of	named entity 'cells' named entity 'monoclonal' named entity 'CD4' named entity 'cytokine storm' named entity 'confirmed' named entity 'killed' named entity 'antibodies' named entity 'T cells' named entity 'BCR' named entity 'isotypes' named entity 'ANALYSIS' named entity 'LEAD' named entity 'RECOVERY' named entity 'SARS-COV-2' named entity 'CELLS' named entity 'COMPARED' named entity 'GREATER' named entity 'RECENTLY' named entity 'target' named entity 'pairing' named entity 'integrated' named entity 'CD4+' named entity 'Our' named entity 'recovery' named entity 'highly' named entity 'remains' named entity 'memory cells' named entity 'The strongest' named entity 'Our' named entity 'TNFSF13' named entity '10X Genomics' named entity 'monocytes' named entity 'PHEIC' named entity 'IL18' named entity 'monocyte' named entity 'preprint' named entity 'diarrhea' named entity 'preprint' named entity 'CD14' named entity 'COVID' named entity 'preprint' named entity 'DUSP1' named entity 'influenza' named entity 'fatigue' named entity 'IL-18' named entity 'scRNA-seq' named entity 'IgA' named entity 'signaling pathway' named entity 'CSF2' named entity 'human cytomegalovirus' named entity 'antiviral drugs' named entity 'COVID' named entity 'CSF1' named entity 'CCR5' named entity 'gene expression' named entity 'IL-18' named entity 'medRxiv' named entity 'CD14' named entity 'COVID' named entity 'multiple organ failure' named entity 'COVID-19' named entity 'myeloid cells' named entity 'cytokines' named entity 'peer review' named entity 'downregulated' named entity 'MPB' named entity 'HCs'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software